Financial Results for the Quarter Ended December 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Parnax Lab Ltd (BSE: 506128) announced its unaudited Q3 FY26 (quarter ended December 31, 2025) and 9M FY26 results on February 13, 2026. On a standalone basis, revenue from operations rose to Rs 270.82 lakhs (vs Rs 98.63 lakhs in Q3 FY25), with profit after tax at Rs 70.91 lakhs (vs Rs 15.78 lakhs) and EPS of Rs 0.62. On a consolidated basis (mainly subsidiary Naxpar Pharma Pvt Ltd, which dwarfs the parent), revenue from operations grew to Rs 6,294.15 lakhs (vs Rs 4,021.61 lakhs in Q3 FY25) and PAT after minority interest was Rs 271.47 lakhs (vs Rs 121.02 lakhs), translating to EPS of Rs 2.37. For 9M FY26, consolidated revenue rose to Rs 17,891.89 lakhs (vs Rs 13,869.93 lakhs) and PAT to Rs 960.03 lakhs. A one-time exceptional charge of Rs 113.80 lakhs (consolidated) was booked due to the new Labour Codes notified in November 2025.
Strong year-on-year growth in both standalone and consolidated numbers, with consolidated profit roughly doubling Q-o-Q on a comparable basis; the standalone figures reflect Parnax's role mainly as a holding company, while real operating momentum sits in subsidiary Naxpar Pharma. Investors should watch the standalone vs consolidated gap and any further Labour Code-driven exceptional items.